STEM CELL-LIKE CELLS

Abstract: The invention relates to the field of embryology, embryogenesis, molecular genetics, (veterinary) medicine and zoo-technical sciences, and to the generation of stem cell-like cells. The invention provides a method for obtaining a stem cell-like cell from a sample taken from a multicellular organism, preferably an organism with some measure of differentiated tissue, thus preferably being beyond the morula stage, comprising culturing cells from said sample and allowing for transcription, translation or expression by at least one of said cells of a gene or gene product that in general is differentially expressed at the various different phases of embryonic development of the organsim as described above.

Description: Title : Stem cell-like cells The invention relates to the field of embryology, embryogenesis, molecular genetics, (veterinary) medicine and zoo-technical sciences, and to the generation of stem cell-like cells. A particular problem in embryology is the understanding of appearance, during development, of complexity of form and function where previously no such complexity existed. Historically two contrasting points of view have been held on this problem. One of these, the so-called theory of epigenesis, considered that during development there is actually the creation of new structures; whereas the other, the theory of preformation, maintained that a pre-existing diversity is already present in the fertilized egg (or in the sperm) and that future development consists merely in the unfolding and rendering visible of this innate diversity. The embryological investigation of the past hundred-and-fifty years have demonstrated most conclusively that the actual processes of development are of an epigenetic nature but the doctrine of preformation has been reintroduced, in a much modified form, in the explanation of the facts established by modern genetics. Classically, the fundamental morphogenetic mechanisms during embryonic development are described under the headings oi growth, differentiation and metabolism. Growth is increase in spatial dimensions and in weight; it may be multiplicative (increase in number of nuclei and (or) cells), auxetic or intussusceptiυe (increase in the size of cells) or accretionary (increase in the amount of non-living structural matter). Differentiation is seen as an increase in complexity and organization. This increase may be in the number of variety of cells and may not at first be apparent ("invisible" differentiation, e.g. determination of fates, segregation of potencies, but, when apparent ("visible" or "manifest" differentiation), constitutes histogenesis, the formation of differentiated or somatic tissue. Metabolism includes the chemical changes in the developing organism. In the normal development of an embryo these fundamental ontogenetic processes are all closely interlinked, constituting an integrated system. They fit in with each other in such a way that the final product comes into being by means of a precise co-operation of reactions and events. From a descriptive point of view the principal stages in embryological development leading to the formation of differentiated tissue within the developing organism can be described in stages. A first phase comprises maturation. The process associated with maturation of the female and male germ cells (gametes) including the reduction (meiotic) division. The mature gametes (ova in the female, spermatozoa in the male) are highly specialized cells which when fully differentiated do not usually five long unless they take part in fertilization. Fertilization is the fusion of a female and a male gamete which results in the formation of the zygote or fertilized ovum. The zygote, although resulting from the fusion of two highly speciaHzed cells, is typically regarded as being the most unspecialized (undif erentiated) of all metazoan cells, being the totipotent, pluripotent or stem cell from which a new individual and differentiated somatic (adult) tissue can develop. The process of differentiation, comprises forward differentiation from this toti- or pluripotent cell to specialized cells that have much more restricted potency but also transdifferentiation is observed where cells with distinct characteristics develop into cells with other distinct characteristics. After fertilization the zygote soon undergoes repeated subdivision or cleavage by mitosis so that a number of cells, blastomeres, each much smaller than the ovum itself, is produced. After a certain number of cell divisions (generally at the 8-16 cell stage), the developing organism is called a morula. Typically, the individual cells of a morula, or at least the greater part of it, are still pluripotent, separation of cells from the morula stage can lead to the production of several new (cloned) individuals, stemming from one zygote, and at the morula stage the organism is in general seen as mainly comprising undifferentiated tissue. However, at some time at the end of cleavage the blastomeres are eventually grouped to form a hollow sphere of cells, the blastula or, in mammals, the blastocyst. In this blastula stage, the organism is in general seen as comprising for the first time some measure of differentiated tissue, whereby totipotent or pluripotent cells can mostly be found in the inner cell mass (ICM) of the blastula. Most of these cells also differentiate further, some of these become the so-called adult stem cells, but most differentiate into the speciaHzed ceU type to which they are being destined. A subgoup of stem cells, also caUed primordial germ cells, are kept in stock for the formation of gametes for a future generation. Experiments on, and intravitam staining of the blastulae of lower vertebrates, especially Amphibia, have made it possible to deHmit the future fated of aU regions of the blastula and thus to ascertain their potency, i.e., what locaHzed areas become in normal development. The different areas of the blastula can thus be referred to as presumptive organ regions, e.g. one region is presumptive notochord, another presumptive neural plate, etc. It is the blastocyst, which in mammals proceeds to implantation in the uterus. The blastula stage is succeeded by the gastrula which results from changes in position and displacements (morphogenetic movements) of the various presumptive regions of the blastula. In normal development the process of formation of the gastrula, or gastrulation, results in certain surface regions of the blastula becoming invaginated within the blastular cavity to form the endoderm, notochord and mesoderm, the tissue undergoes visible differentiation. The region through which invagination occurs is called the blastopore. The ceUs which remain on the blastular surface constitute the ectoderm, from which the epidermis and the neural plate axe derived, and by their expansion and multipHcation they graduaUy replace the areas of presumptive endoderm, notochord and mesoderm as the latter are invaginated. Gastrulation results in the estabHshment of the three primary germ layers, endoderm, mesoderm and ectoderm, again comprising, albeit somewhat mere differentiated, stem ceUs, and brings the presumptive organs of the embryo into the positions in which they will undergo their subsequent development. In reptiles, birds and mammals this gastrulation period is represented by the embryonic disc and primitive streak stages. The gastrula stage is foUowed by the neurula stage in which the neural plate and the axial embryonic structures are elaborated. In Amphibia this is known as the neurula. This stage corresponds roughly to the somite stages in human development. At the end of the neurula, or somite stage of development the general pattern of the embryo is weH estabhshed and later embryos are said to be in the so-called functional period of development. The earHer embryonic stages, which have been described above, result in the appearance of the general embryonic pattern before the onset of specific function in the primordia of the different organs and tissues which are differentiated in these stages. Functions in the general sense are carried out at all times as aU the cells are undergoing metaboHc changes and must "work to Hve". But with the onset of specific functions such as beating of the heart, contraction of muscles, secretion by glands, etc., the embryo enters on what may be called the functional period of development. Different organs, of course, commence to function at different times and no sharp distinction can be made between pre-functional and functional stages; growth and differentiation proceed in both. Nevertheless it is useful to consider the process of earHer stages as blocking out the main embryonic organ systems which will subsequently be elaborated under the influence of the specific functions which they perform. The functional influence does not, by any means, replace the genetically determined general pattern of development, but, in the development of many organs and tissues (e.g., the heart and blood vessels and the skeletal system), the effect of the function of an organ on its development is considerable. The functional stage of development results in the different organs and tissues coming into physiological relationship with each other and, therefore, in a degree of integration of total function which cannot exist in earHer stages. The integration is facihtated, and indeed rendered possible, by the differentiation of the vascular and nervous systems and the onset of function in the endocrine glands. When the developing organism has entered such a functionaUy differentiated stage in its development, most if not aU requirements underlying further developments in the foUowing foetal, post-natal or adult stages of the individual have been met. In short, aU multiceUular organisms are in general formed from a single pluripotent egg ceU which give rise to further totipotent stem ceUs, the embryonic stem (ES) ceUs. ES ceHs are clonal cells, for example derivable from the inner cell mass of an developing blastula and are capable of adopting aU the ceH fates in a developing embryo. They form the pluripotent ceUs of the inner cell mass of mammalian pre-implantation embryos. These ceUs can in general be isolated and maintained in-vitro as pluripotent cells or stem ceU-Hke cells, and now can even give rise to new (cloned) individuals (see also http://www.nuffieldfoundation.org bioethics). Genetically modified mouse stem cells have been cultured together with feeder ceUs or co-cultured with mouse ES ceUs or ceU aggregates such as embroid bodies to induce differentiation. However, to isolate or study the fate of stem cells, also under different inductive environments a cumbersome selection procedure is required. Such a selection method generally involves modification of stem ceUs by genetic means. Stem cells for example need essentially be modified to express a resistance marker (for example a neomycin resistance) gene in order to eventually eHminate the feeder or co-culture ceUs and select specificaUy for stem ceUs. For this technology to have appHcation in medicine or even for zoo- technical apphcations, the use of a selection system based on the detection of a resistance marker is not desirable. ES ceUs in general have an indefinite life span and can proliferate extensively when propagated under appropriate culture conditions involving the use of embryo-derived feeder ceUs or media containing lymphocyte inhibitory factor (LIF) (e.g in the case of mouse ES cells). When for example injected into mouse blastocysts, in-υitro propagated totipotent or pluripotent embryonic stem cells can contribute to aH tissues of the recipient embryo as well as to the germ Hne and be a source of new (cloned) individuals. In addition, these pluripotent embryonic stem cells can be induced to differentiate in-υitro yielding differentiated derivatives representative of aU three germ layers including neuronal, myocardial and endotheHal ceUs. Functionally differentiated organisms with differentiated tissues such as mesodermal, ectodermal, endodermal, or even adult or somatic tissues may still contain a variety of ceUs that have normal functions in tissue such as the continuous generation of new ceUs, also in response to injury and aging (i.e ceU renewal). Such "differentiated or adult stem ceUs" have for example been found in bone marrow, bone marrow stroma, muscle and brain. Adult somatic stem ceUs have similar, albeit some restricted capacity of self-renewal and may give rise to daughter cells with the same potential as weU as daughter ceUs with a more restricted differentiation capacity. The differentiation potential of stem ceUs in differentiated tissues is in general thought to be Hmited to cell Hneages present in the organ from which they were derived, excluding of course the potential of those primordial germ ceUs that are required for gamete formation. However, this concept is rapidly changing as somatic stem ceUs, shown herein, are in fact highly plastic ceUs and amenable to change given the appropriate environment, not acting only in tissue in which they reside, but may be recruited out of circulation and enter in regenerating of tissues at distal sites. The invention provides a method for obtaining a dedifferentiated or transdifferentiated stem ceH-like ceU from a sample taken from a multicellular organism, preferably an organism with some measure of differentiated tissue, thus preferably being beyond the morula stage, comprising culturing ceUs from said sample and aUowing for transcription, translation or expression by at least one of said cells of a gene or gene product that in general is differentiaHy expressed at the various different phases of embryonic development of the organism as described above. Measuring Oct4 expression is a bona fide marker for determining the presence of de-differentiated pluripotent human ES- equivalent cells. The same is true for expression of the markers such as SSEAl, SSEA3, TRA-1-60, Tra-1-81 or alkahne phosphatase. Dedifferentiated ES- equivalent cells are different with respect to isolated hES ceUs in that ES- equivalent cells are essentiaHy feeder ceU independent for prohferation as ES- equivalent ceUs. De-differentiated ES-equivalent cells have similar therapeutic potential. Hereby the invention provides for a dedifferentiation and/or selection of at least one or some ceUs from said sample for stem ceU-Hke ceU characteristics based on for example the transcription (and possible further translation) of distinct gene products or the presence of distinct transcription factors (detectable by for example detecting relevant promoter activity or detecting other relevant gene products such as mRNA or (poly)peptides derived from a gene that is for example differentiaUy expressed at the morula stage versus the neural stage, or the blastula stage versus the functional stage, or the blastula stage versus the adult stage. By allowing the ceUs from an already forward differentiated or speciaHsed tissue to again or preferentiaHy transcribe early phase genes that are no longer transcribed, or alternatively, to suppress or down-regulate transcription of later phase genes, said dedifferentiation or selection of a stem ceU-Hke ceU is provided, even from an already functionaUy differentiated organism as described above. The invention thus provides a dedifferentiated stem ceU or stem ceH-Hke ceU, and ceU cultures or ceU Hneages derived thereof. The pluripotency of stem ceH-Hke hES-eq ceUs has been estabHshed by production of teratomas foHowing transplantation in immunodeήeient (SCID) mice, and by injection of hES-eq cells in mouse blastocyst and assessment of the level of chimerism based on (i) detection of human or isogenic cell surface marker; (ii ) the expression of human genes in developing tissues using RT-PCR and human gene-specific primers and (in) expression of a hES-eq expressed reporter (GFP, LUC, LacZ) foUowing stable or transient expression of this gene in hES-eq cells , foHowed by co-culture with undifferentiated ceHs such as inner ceU mass derived ceUs, for example with aggregates of such cells or injection of hES-eq ceUs into the amniotic cavity of chick stage 4 embryo's and detection of chimerism in the developing tissues by analysis of ceU surface marker expression and RT-PCR using human gene- specific primers. Totipotent dedifferentiated stem ceHs as provided herein are obtained from for example human tissue. These hES-eq(uivalent) ceUs are characterised by expression of the stem ceU-specific transcription factors Oct4, Sox2 and UTFl, specific pattern of expression of the cell surface markers stage-specific embryonic antigens SSEA-1 and SSEA-3, TRA-1-60 and TRA-1-81 and alkaHne phosphatase, specific gene expression profiles as determined by DNA gene expression micro-arrays, and the capacity to form differentiated derivatives from embroid bodies foUowing aggregation in the presence of retinoic acid or DMSO and expression of ceU Hneage markers (depending of the treatment) Troma-1 (endoderm derivatives), Neurofilament type-1 (neuronal derivatives), Cardiac Myosin Heavy chain (cardiac muscle), expression of telomerase activity and normal karyotype corresponding with the sex of the donor. From other mammals, similar ES-ceUs were obtained demonstrating similar (species- specific) characteristics. Other procedures provided herein and aUowing faciHtating the recovery of dedifferentiated stem ceUs or stem cell-like ceUs involve manipulation of gene expression affecting cell cycle progression in the G0-G1 phase of the cycle including pre-treatment with transforming growth factors for transient induction of ceH cycle arrest , or timed addition of extraceUular factors that block differentiation at early stages of development i.e. nodal to antagonize BMP effects or contribute to dedifferentiation, such as by Trichostatin A (TSA), and by removal of differentiating agents such as retinoids from Fetal Calf Serum (FCS) containing media, or timed addition of extraceUular factors that sustain the proliferation of ES-like ceUs i.e. LIF, growth factors including FGF's, PDGF's and interleukins, or co-culture of selectable adult stem ceUs as indicated above with pluripotent ES ceUs (mammalian, human, primate) classified as such; human embryonal carcinoma ceUs classified as such i.e. N-tera-2; yolk-sac tumor ceU Hnes classified as such, or culture of somatic stem ceUs with conditioned medium derived from the above ceUs Hnes, or isolated factor(s) present in the conditioned medium of the ceU Hnes indicated above, in particularly in those overexpressing UTFl. In the case of the production of dedifferentiated stem ceUs from humans, tissue samples were obtained under condition of (patient) informed consent and experiments involved controUed laboratory processes. The isolation of human ES equivalent (hES-eq) ceUs from pre- and post-natal and adult human tissue may further involve the foUowing isolation and selection of hES-eq ceUs on the basis of expression of Oct4 promoter driven ceU surface marker(s) (Schoorlemmer et al., Mol. CeU. Biol. 14:1122-1136, 1994) aUowing specific recognition of the ceU surface expressed molecules by specific antibodies. Isolation procedures may involve separation of hES-eq ceUs with magnetic bead or fluorescence activated ceU sorting (FACS). Oct4-promoter driven expression of Green Fluorescent Protein (GFP) and isolation of GFP-expressing ceU by FACS is provided as weU Oct4-promoter driven expression of the neomycin resistance gene and selection of G418 resistant ceUs is optional. Such a dedifferentiated stem ceU, or stem ceU-Hke ceU, as provided herein can be used for aU purposes that seem fit as use for stem ceUs in general, but offer also distinct advantages beyond current avaflable stem ceUs. In one specific embodiment, it is now provided to take a sample from an individual suffering from a disease (in particular helpful, when the organism is human, in human medicine for for example bone-marrow deficient patients, patients suffering from Parkinson disease or Alszheimers disease or diabetes or other disease where suppletion or transplantation with speciaHsed ceUs is contemplated) or otherwise in need of transplant treatment , treat the sample as described herein, obtain a dedifferentiated stem ceU from said individual, grow it into a culture of stem ceU-Hke ceUs, provide, if required, for forward differentiation of said culture towards a more differentiated or required speciaHsed ceU type, and use such a culture or parts thereof as graft for treatment of the exact same individual. No major adverse immune response are to be expected when the graft is, so to speak, put back into the individual, however now provided with desired functionaHty's deemed necessary for treatment. In particular, said ceUs need no recombinant engineering to provide an immunological match with the recipient, the recipient being also the donor of the ceUs to begin with. In other words, the recipient can be his or her own donor. A ceU as provided herein can also be used to grow distinct tissue types, such as (heart) muscle ceUs, blood ceUs, blood vessel ceUs, cartilage or bone tissue, neural ceUs, skeletal tissue, and so on, for which, again no immunological match is required when placed back into the donor/provider of the source of the graft. Of course, these ceUs lend themselves also to the provision of said immunological matches in case other recipients are contemplated, using methods known in the art and classical employed with the embryonic stem ceUs that give rise to speciaHsed tissue or ceUs. Of course, a ceU as provided herein finds its use also in providing new (cloned) individuals, which is in particular advantageous, when the organism is a vertebrate such as a fish (salmon, trout, eel), poultry (chicken) or mammalian (mice, rats, guinea pigs, or other smaU laboratory animals, or farm animals like ruminants or pigs) in the field of the creation of (near identical or cloned) experimental animals or farm-animals or animals for the production of xenotransplant-tissue (often pigs are used) or other desired (recombinant) products. Again, a major advantage of the method as provided herein lays in the fact that such ceUs can now be obtained from functionaUy differentiated or even speciaHsed adult somatic tissue, such as muscle, brain, blood, none marrow, Hver, mammary gland, and so on, aUowing to first select the desired animal from amongst other related but less desirable animals (e.g. on production characteristics), and than cloning it, using for example an easUy obtainable tissue biopsy as sample for the provision of the desired stem ceU-Hke ceU or ceUs from which cloning can commence. Such dedifferentiated ceUs as provided herein can, if required in an intermediate step, be injected into a (if desirable an unrelated) developing embryo (preferably blastula stage) and develop into a chimeric organism from which primordial germ ceUs or gametes with the desired specificity can be harvested, but can also be used for direct embryonic development. In a preferred embodiment, a method according to the invention is provided wherein said somatic ceUs from said sample are cultured in the relative absence of a differentiation factor such as different members of the steroid- hormone receptor superfamUy (nuclear receptors). ARP-1, RAR (retinoic acid receptor) but preferably in the relative absence of retinoid or retinoic acid or analogue thereof. This aUows for routing said ceU back to a dedifferentiated ot totipotent state, as characterised by the differential expression of differentiation factor or retinoic acid induced or suppressed genes or fragments thereof. Culture medium can be deprived of retinoids or retinoid activity by for example charcoal filtration of the medium itself or its constituting components such as the serum (preferably bovine calf serum, preferably free of specified pathogens is used), measuring resulting activity and using the medium sufficiently deprived of said activity. Growth media, such as synthetic media, are otherwise produced and used as known in the art of ceU culture, in particular of stem ceU culture. The invention also provides further comprising a selection method preferably not based on the genetic modification of somatic ceUs for the identification of embryonic stem ceU like ceUs from amongst a population of ceUs in adult somatic tissue. Dedifferentiated adult somatic ceUs which have this broad differentiation repertoire are herein also referred to as a somatic stem ceU embryonic stem ceU equivalent (SSCES-eq) or stem ceU-Hke ceU. SSCES-eq have characteristics that are very similar or even indistinguishable from embryo- derived ceUs (ES) and have a developmental repertoire that is close or even identical to that of ES ceUs. This system is based on the observation that specific marker genes such as the weU known transcription factor Oct 4 and for example its targets kFGF, UTFl and SMAD regulated target genes are differentiaUy expressed during the developmental processes observed in the growing embryo. These de-differentiated SSCES-eq can be multipHed in vitro and can under the right circumstances give rise to an almost unHmited source of stem ceUs to be used in a variety of ways. Dedifferentiated somatic stem ceUs from a single donor can be made recipient-independent and broad range appHcable by genetic inactivation in vitro of the MHC locus. Therefore this invention provides the means to treat more easUy individual patients, in a strict donor-recipient relationship, with SSCES-eq ceUs derived from their own tissues with properties equivalent to ES ceUs speciaHsed for a given task. Furthermore it provides the means to treat various diseases in different affected individuals with general source of de-differentiated SSCES-eq ceUs. The invention shows that adult somatic stem ceUs, although more speciaHsed than pluripotent ES-ceUs can be used as alternative source for embryo-derived ES-ceUs, for the purpose of repairing or replacing body tissues (for example blood, nerve and myocardial tissues), with the main advantage that immunological matching is nor required. The present invention provides a method for in-vitro selecting a somatic stem ceU like ceU from differentiated tissue material or samples comprising culturing ceUs from said material under conditions aUowing for induction of expression of essential pre-implantation (early blastocyte stage in mammals) gene products and/or suppression of expression of non-essential pre-implantation gene products. A somatic stem ceU or tissue herein refers to any differentiated 'body' ceU or tissue be it of mesodermal, endodermal or ectodermal descent ( for example blood, immune system, nerve, myocardial, muscle, intestinal tissue). Further the invention provides a method for in-υitro selecting a somatic stem ceU like ceU from post-implantation material comprising culturing ceUs from said material under conditions aUowing for induction of expression of essential post- implantation gene products and/or suppression of expression of non-essential pre-implantation gene products. The invention provides a method of selection of a stem ceU like ceU (SSCES-eq) based on detecting differences in gene expression patterns between genes differentiaUy expressed at different stages of embronic development, in mammals for example identifiable as pre- and post-implantation stages. Methods to detect differential gene expression patterns are known in the art and comprises methods aimed at detecting 'nucleic acid' and or 'amino acid'. 'Nucleic acid' herein refers to an oHgonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represents the sense or antisense strand. 'Amino acid' herein refers also to peptide or protein sequence. Included in the scope of the invention is detection of different aUeles of the polypeptide encoded by nucleic acid sequences or gene of interest. As used herein, an 'aUele' or 'aUeHc sequence' is an alternative form of a polypeptide. AUeles result from a mutation [eg. a change in the nucleic acid sequence, and generally produce altered mRNA or polypeptide whose structure or function may or may not be altered]. Any given polypeptide may have none, or more aUeHc forms. Common aUeHc changes that give rise to aUeles are generally ascribed to natural deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence. DeHberate amino acid substitution may be made on the basis of similarity in polarity, charge, solubiHty, hydrophobicity, and or the amphipathetic nature of the residues as long as the biological activity of the polypeptide is retained. A 'deletion' is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent. An 'insertion' or 'addition' is that change in nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturaUy occurring polypeptide(s). A 'substitution' results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively. Included is a polypetide variant. A Variant' of a polypeptide is defined as an amino acid sequence that is different by one or more amino acid 'substitutions'. A variant may have 'conservative' changes, wherein a substituted amino acid has si Uar structural or chemical properties eg replacement of leucine with isoleucine. More rarely a variant may have 'non- conservative' changes (eg replacement of a glycine with a tryptophan). SimUar minor variations may also include amino acid deletions or insertions, or both. Methods to detect differential gene expression patterns are known to those skilled in the art. These procedures include, but are not Hmited to DNA- DNA or DNA-RNA hybridisation. The form of such quantitative methods may include, Southern or Northern analysis, dot/slot blot or other membrane based technologies; PCR technologies such as DNA Chip, Taqman®, NASBA, SDA, TMA, in-situ-hybridisation, protein bioassay or immunoassay techniques ELISA, IFA and proteomic technologies. Other evolving technologies such as 'metabolomics' can be employed to look at changes in metaboHc profiles between tissues and/or ceU types. The invention also provides a method of selection whereby said material is derived from vertebrate tissue and/or ceUs. The term vertebrate refers to a higher Hfe form having a spinal column. One preferred embodiment is that the somatic stem ceU like ceU (SSCES-eq) selected is from adult somatic tissue. Included in the scope of the invention is somatic stem ceUs obtainable from primate somatic tissues. 'Tissue' herein refers to a coUection or aggregate of individual ceU types. The invention further provides a method of selection whereby said tissue comprises muscle tissue and/or bone marrow tissue and/or bone marrow stroma and or nerve tissue and/or brain tissue and/or blood. Unlike ES ceUs the dedifferentiated stem ceUs as provided herein can be derived from a multitude of tissue types. These ceUs are also derivable from bone marrow, bone marrow stroma, muscle and brain tissue. The invention further provides a method of selection whereby said tissue is adult tissue. One preferred embodiment is that the somatic stem ceU like ceU is obtainable from nerve tissue and/or bone marrow tissue and/or bone marrow stroma and/or muscle tissue and/or brain tissue and/or blood, more preferably human. The invention further provides a method of selection comprising selecting said ceU from the ectoderm and/or mesoderm and/or endoderm layer of said tissue. The invention further provides a method of selection comprising selecting said ceU by detection of expression of ceU-specific transcription factors Oct4 and/or Sox2 and/or UTFl or homologues or orthologues thereof. The tissue-specific transcription factors Oct4 and/or Sox2 and/or UTFl are required for the development of a precise somatic stem ceU lineage. Hence the dedifferentiated stem ceU provided herein can be identified on the basis of expression of these stem ceU-specific transcription factors. The definition 'homologue' is a term for a functional equivalent. It means that a particular subject sequence varies from the reference sequence by one or more substitutions, deletions, or additions resulting in 'amino acid' that encode the same or are functionaUy equivalent, the net effect of which does not result in an adverse functional dissimUarity between the reference and the subject sequence. Orthologues are simUar genes found with other species. The invention further provides a method further comprising selecting said ceU by detection of expression of ceU surface markers stage specific embryonic antigens SSEA-1 and/or SSEA-3 and/or TRA-1-60 and/or TRA-1-81 and/or alkahne phosphatase or analogs thereof. The invention further provides a method of selection whereby said somatic stem ceU like ceU has telomerase activity. The invention further provides an isolated somatic stem ceU obtainable from adult somatic tissue having telomerase activity. 'Telomerase' activity herein refers to the activity of a specific enzyme termed telomere terminal transferase which is involved in the formation of telomere DNA. Telomers are required for repHcation and stable inheritance of chromosomes. The invention further provides a method of selection whereby said somatic stem ceU like ceU has trans- differentiation capacity. Adult somatic stem ceUs have a high trans- differentiation capacity. By trans-differentiation capacity it is meant that somatic stem ceUs have the capacity of indefinite self-renewal by producing a multitude of daughter ceUs through repeated divisions. They give rise daughter ceUs with the same potential, as weU as daughter ceUs with a more restricted differentiation capacity. Neuronal stem ceUs can give rise to blood ceUs after transplantation into the blood of irradiated stains of mice. Also muscle progenitor ceUs have been shown to be capable of trans differentiation into blood. Furthermore, bone marrow stroma ceUs transplanted to the brain can generate astrocytes and hematopoietic stem ceUs can give rise to myocytes. The invention further provides a somatic stem ceU like ceU comprising recombinant nucleic acid. ClassicaUy, ES ceUs are seen as extremely useful for creating transgenic animals, the the dedifferentiated stem ceU as provided herein is equaUy suitable. Methods to transduce stem ceUs are known in the art. A 'gene deHvery vehicle' herein is used as a term for a recombinant virus particle or the nucleic acid within such a particle, or the vector itself, wherein the vector comprises the nucleic acid to be dehvered to the target ceU and is further provided with a means to enter said ceU. The invention provides an isolated stem ceU like ceU obtainable through selection capable of cHnical use. A dedifferentiated stem ceU or ceUs from a single donor can be made recipient-independent and broad range appHcable by genetic inactivation in vitro of the MHC locus. Included in the scope of the invention is a pharmaceutical composition comprising a somatic stem ceU like ceU or culture transduced with a gene deHvery vehicle, to generate different tissue types for appHcation in gene therapy. One usage is the generation of different types of tissue and/or tissue renewal. Another is the repair and/or replacement of different types of tissue. These tissues derived from somatic stem ceU like ceUs could be administered to a patient by transplantation into host tissue or by grafting for use in the treatment of by way of example Parkinson disease and/or cardiovascular disease and or Hver disease. For example adult somatic stem ceUs or the dedifferentiated pluripotent ES-like ceUs can be obtained for muscle tissue or cordial blood of a given patient donor, dedifferentiated (multipHed) in-vitro, and can then be appHed for brain tissue repair as donor recipient. This source of stem ceUs can be used in any kind of tissue renewal and/or repair and/or replacement in cases such as, but not Hmited to Parkinson disease, cardiovascular diseases, Hver disease. Another preferred embodiment of the invention relates to the production of non donor-specific pluripotent ES-like ceUs for use in non-donor recipient tissue repair and/or renewal and/or replacement treatments. Dedifferentiated somatic stem ceUs from a single donor can be made recipient-independent and broad range appHcable by genetic inactivation in vitro of the MHC locus. This has an advantage in that a general source of human stem ceUs can be appHed for tissue repair and/or renewal and/or replacement treatments without tissue rejection problems arising. The invention further provides use of a ceU or culture or graft or animal as provided herein in studying the biology of vertebrate development, in transplantation, in drug screening and drug discovery and in cosmetic surgery, whereby again immunological mismatches can be avoided. Included in the scope of the invention are cross species recipients. Oct 4, a member of the Pou domain, class 5, transcription factors (Pou 5fl) (Genbank accesion S68053) is one of the mammalian POU transcription factors expressed by early embryo ceUs and germ ceUs. It is a marker for PGCs and pluripotent stem ceUs in mammals. The activity of OCT4 is essential for the identity of the totipotent founder ceU population in the mammalian embryo. Oct 4 determines paracrine growth factor signaHng from stem ceUs to the trophectoder, involving the Oct4/Sox2 target gene FGF4. Oct-4 is a transcription factor whose expression is associated with an undifferentiated ceU phenotype in an early mouse embryo and is down-regulated when such ceUs differentiate. Expression of oct-4 in embryonic stem ceUs is controUed by a distal upstream stem ceU specific enhancer that is deactivated during retinoid or retinoic acid (RA) induced differentiation by an indirect mechanism in general not involving binding of RA receptors. Said enhancer is thought to contain no retinoic acid receptor (RA) binding sites. Oct 4 is subject to negative regulation by other differentiation factors such as different members of the steroid-hormone receptor superfamUy (nuclear receptors). ARP-1, RAR (retinoic acid receptor). It has been shown that negative regulation of OCT4 expression during RA induced differentiation of embryonic stem ceUs is controUed by two different mechanisms, including deactivation of the stem ceU specific enhancer and by promoter sUencing by orphan hormone receptors. Oct4 in combination with its co-regulator Sox2 binds to juxtaposed Oct4-Sox2 DNA binding sequences in promoters of a variety of target genes including FGF- 4, PDGF-alpha, Rex-1 and UTFl. UTFl binds to the SMAD binding element (SBE) consisting of the sequence CAGACAG or variants or thereof, which are present in TGF-beta/activin/BMP target genes to mediate SMAD-dependent transactivation. The 3 central nucleotides GAC of the SBE sequence are essential for both Smad as weU as UTFl binding. UTFl forms complexes with the receptor-regulated Smads 1,2,3 and co-Smad4. Furthermore, overexpression of UTFl blocks Smad-dependent transcriptional activation of TGF-beta, Activin and BMP target genes which include the developmental control genes Mix-1 and goosecoid expressed during gastrulation, the ceU cycle inhibitors pl5, pl6 and p21 which block ceU cycle progression, genes promoting ceU adhesion like coUagen, inhibitors of adhesion protein degradation including plasminogen activator inhibitor and the immediate early Fos/Jun genes which play a role in ceU proHferation. A variety of Smad target genes are repressed through histon de-acetylase activity (HDAC) as demonstrated by activation foUowing treatment with Trichostation A. Like Oct4, the expression of UTFl is confined to embryonic stem ceUs. The relationship between expression of Oct4 and its direct target UTFl imphes that loss of expression of Oct4, activates TGF-beta/Activin/BMP signal transduction and target gene regulation. SimUarly, over-expression of UTFl blocks Smad- dependent target gene regulation and ES/EC ceUs differentiation. Alternatively, over-expression of UTFl in adult stem ceUs may resulting in de-differentiation resulting in ceUs with higher Oct4 expression resembHng ES-equivalent ceUs. Leukocyte inhibitory Factor (LIF) is a cytokine that acts through the JAK/STAT3 signal transduction pathway. Components involved in LIF signal transduction include the transmembrane LIF receptor and its dimerizing partner gpl30, the tyrosine protein kinase Jak-2 and trancription factor STAT3. LIF also activates the ERK or JNK/p38 pathways downstream of gpl30 receptors. IL-6 signal transduction involves the IL-6 receptor gp80 and further the components involved in LIF signal transduction. LIF signal transduction supports self- renewal and feeder-independence of mouse ES ceUs. This in contrast to human (primate) ES ceUs that are resistant to the action of LIF and faU to activate STAT3 in these ceUs. This differential sensitivity to LIF may be attributable to high expression of SOCS1, a negative regulator of LIF signal transduction acting at the level of JAK tyrosine kinase activation. The components of LIF signal transduction are expressed at simUar levels in human ES and human mesenchymal stem ceUs. gp80 expression however is expressed in hMSC but not in human ES ceUs. De-differentiation of hMSC to ES-equivalent ceUs therefor results in loss of expression of this gene. In mouse ES ceUs, LIF signal transduction induces, either directly or indirectly, the expression of Sox2, thereby modulating Oct4-Sox2 transcriptional activation, including the expression of UTFl. Regulation of Sox-2 expression in the human ES ceUs is presently unknown. Oct4, Sox2 and UTFl are components of a regulatory system that controls pluripotency of embryonic stem ceUs. Retinoids downregulate Oct4 which induces differentiation. LIF deprivation also induces differentiation affecting the expression of Sox2 at least in the murine system. Oct4 and or Sox2 downregulation UTFl which aUows Smad-dependent transcriptional activation affecting a variety of ceU functions characteristic of the differentiated state. In adult stem ceUs, these effects are reversible leading to de-differentiation and ES- equivalent ceUs characterized by normal OCT4 expression levels. In Niwa Hitoshi et al., Nature Genetics 4, 372-376 (2000), the role of OCT4 as gatekeeper of embryonic stem ceU pluripotency and its role in forward differentiation of ES has been investigated. However, the present invention provides the insight that regained Oct4 expression is Hnked to de-differentiation back to embryonic stem ceU pluripotency, in particular increasing Oct4 expression aUows de-differentiation of a more mature adult ceU into the desired stem ceU, the fact being that Oct4 expression is now defined as a useful marker for analysis of de-differentiation of adult (stem) ceUs to ES-equivalent or ES-ceU like ceUs. Loss of Oct-4 expression results in loss of pluripotency of embryonic stem ceUs and differentiation into trophoectoderm. Saijo Yukio et al., Genes to CeUs, 1, 239-252 (1996), describe the isolation a number of pluripotent ceU- specific downstream target genes of Oct4 that are differentiaUy expressed between undifferentiated pluripotent ceUs and adult (stem) ceUs, and that are also useful markers for the purposes of a method as provided by the invention. Stewart, C.L. , Nature Genetics 4, 328-330 (2000), also highHghts the role as Oct4 as gatekeeper of pluripotency and control of embryonic stem ceU development and differentiation. However, Stewart does not Hnk overexpression of Oct4 with de-differentiation of an adult or somatic stem ceU to an ES- equivalent or ES-like ceU. In Nishimoto Masazumi et al., Mol. CeU Biol. 19, 5453- 5465 (1999) the UTFl gene was identified as a target for the transcription factor Oct4 acting in concert with the transcription factor Sox2. UTFl is expressed in pluripotent stem ceUs and also possibly involved in maintenance of the pluripotent state. Consequently, also UTFl is a useful marker for pluripotency of de-differentiation as provided herein, whUe over-expression in adult ceUs may lead to de-differentiation to ES-equivalent or like ceUs. WO 00 27995 describes the isolation and characterization of human Embryonic Stem ceUs, which however are not obtained by de-differentiation. OCT4 and SSEA4 have been used as markers to define the pluripotency of the isolated ceU Hnes. The isolated human ES ceU require feeder ceUs for prohferation as undifferentiated ES ceUs. Figure legends FIGURE 1. Identification of a RT-PCR primer set that specificaUy amplifies OCT4 in mixed mouse/human RNA samples. M: Mw markers; P19 EC: mouse EC ceU Hne; P19 EC UTF: UTFl expression in P19 mouse EC ceUs; NteraD2: human EC ceU Hne; hu ES: human Embryonic Stem ceUs; huMSC: human Mysenchymal Stem CeUs; beta2 micro-globuHn: human beta2 microglobuhn. -RT: RT-PCR without conversion of RNA into cDNA. FIGURE 2. Oct4 in co-cultured P19 EC and human Mesenchymal Stem CeUs Lane M: Mw markers; lanes hMSC: human Mesenchymal Stem CeUs; lanes P19: P19 EC ceUs; lanes CO: P19 EC and hMSC co-cultured for 5 days; lane beta-2 and GAPDH: expression of human-specifc beta-2 microglobuhn and mouse GAPDH expression in co-cultured ceUs; lane beta-2 and GAPDH -RT: PCR without conversion of RNA in cDNA. HuOCT, hUCT4 28cy and 32 cy: human OCT4 expression and human OCT4 expression after 28 and 32 PCR cycles; h/m Oct4: expression of mouse and human Oct4. FIGURE 3: SSEA4 labeHng of human Mesenchymal Stem CeUs and human Mesenchymal Stem CeUs in co-culture with P19 EC ceUs. SSEA4: SSEA4 staining. Dil: human hMSC labeled with Dil in co-culture with P19 EC ceUs. DAPI: visuaHzation of nuclei. Transmission: visuaHsation of ceUs. The SSEA4, DAPI and transmission pictures represent the same microscopic field and can be superimposed. FIGURE 4. In vitro translated UTFl binds to the sequence of the SMAD binding element (SBE). In vitro translated Myc-UTFl (indicated as myc cl 8.8) was directly Western blotted (1% of total) or Western blotted after binding to biotinylated SBE foUowed by pricipitation using avidin-conjugated agarose beads. Myc-UTFl (myc-clone 8.8) was detected by anti-Myc antibody in the total lysate as weU as after binding to the SBE oHgonucleotide sequence. FIGURE 5. UTFl blocks TGF-beta and SMAD3/4-dependent transactivation of the (SBE)4- LUC reporter.. SBE: transfection of SBE alone; TGF; SBE transactivation foUowing TGFbeta stimulation; TGF-beta C18.8: TGF-beta induced SBE transactivation in the presence of over-expressed UTFl. Lanes S3/4: SBE transactivation foUowing over-expression of Smad3/4, Smad3/4 and stimulation by TGF-beta, over-expression of Smad 3/4 in the presence of over-expressed UTFl (cl 8.8) and over-expressed Smad3/4, over-expressed of UTFl and stimulation with TGF-beta. SBE transactivation is indicated as fold induction over non SBE-LUC reporter transfected control ceUs. Further experimental procedures 1. CeU culture and media (a) human Mesenchymal Stem CeUs (for example as identified in US patent: 5,486,359) Human Mesenchymal Stem CeUs were obtained from Poietics (BioWhittaker). CeUs were grown in mesenchymal stem ceU basal medium (MSCBM) supplemented with mesenchymal stem ceU growth supplement, L-glutamine, Streptomycin and PeniciUin according to the instructions of the suppHer. CeUs were cultivated for more then 15 passages without notable morphological alteration or change in marker expression. Cultures were maintained in 5% CO 2 at 37°C is a humidified atmosphere. (b) human Neuronal Progenitor CeUs Human Neural Progenitor CeUs were obtained from Poietics (BioWhittaker). CeUs were propagated as neurospheres in growth medium consisting of Neural Progenitor Maintenance Medium and recommeded supplements (h-bFGF, h- EGF, neuronal survival factor, gentamicin and amphoceritin-B according the instructions of the suppHer. Cultures were maintained in 5% CO2 at 37°C is a humidified atmosphere. (c) P19 and NteraD2 EC ceUs P19 and NTeraD2 were obtained from the American Type and Culture CoUection (ATCC) and cultured in alpha-minimal essential medium (alpha-MEM) supplemented with 7.5% Normal Calf Serum (NCS) and 2.5% Fetal Calf Serum (FCS). Medium was supplemented with peniciUin (100 U/ml) and streptomycin (100 microgam/ml) and maintained in a 5% CO2 atmosphere at 37°C. (d) co-cultures of P19 EC and hMSCs CeUs were grown for 5 days in MSCBM (hMSCs and co-cultures) or alpha-MEM (P19 ceUs) on glass covershps in 6-weUs plates. P19 ceUs monoculture: 5000 ceU/weU; hMSC monoculture 20.000 ceUs per weU; co-culture: 3000 P19 ceUs and 20.000 hMSCs per weU. Before plating ceUs for co-culture, a number of hMSCs were labeled using the Hfe stain Dil (l,l"-dioctadecyl 3,3,3',3'-tetramethyHndocarbocyanine). CeUs were labeUed with Dil (5μl/ml) for 10 minutes and washed 3 times with fresh medium. After staining the ceUs were kept in the dark to prevent decay of fluorescence. 2. Protocol for charcoal stripped serum to remove retinoids Day 1: Prepare dextran-coated charcoal suspension Add 450 ml of tissue quaHty H2O to 50 ml of TRIS/HCL 0.1M, pH 8.0 Dissolve in this buffer 0.25 gram of Dextran T500 Pharmacia, nr. 17.0320.01 Add 2.5 grams of activated charcoal Fluka cat.nr. 05120 or Sigma C-5260 Stirr overnight at 4°C in tightly locked vessel Day 2 Heat 200 ml of Fetal Calf Serum (FCS) for 30 minutes at 56°C in a water bath. In the meantime fill 12 x 50 ml (plastic) centrifuge tubes with the charcoal suspension. Spin in swing-out rotor, 20 min, 1000 x g. Discard the supernatant. Remove as much fluid as possible without touching the peUets. Add the serum to 6 charcoal peUets and resuspend the peUets in the serum. Incubate in a water bath at 45° for 45 min, whUe shaking. Spin in swing-out rotor, 20 min, 1000 x g. Add the serum supernatant to the 6 remaining charcoal peUets and repeat the whole procedure. Add the serum to 6 clean centrifuge tubes and spin again. Pool the serum in a clean bottle and filter/sterilize before freezing. Retinoids or retinol derivatives are for example aU-trans-reϋnyZ esters, aU-trans- retinol, 3,4-didehydro-retinol, 4-oxo-retinol, aU-trans-retinal, 4-oxo-retinal, beta- carotene, aU-trans-retinoic acid, 18-hydroxy-retinoic acid, 4-hydroxy-retinoic acid, 4-oxo-retinoic acid, 9-cis-retinoic acid, or 9-cis-4-oxo-retinoic acid. 3. Antibodies and immunofluorescence. CeUs grown on coversHps were fixed in 4% paraformaldehyde in PBS for 30 min., washed with PBS and incubated for 1 hour at room temperature with the primary antibody. The primary antibodies SSEAl, SSEA4 and OCT4 were used at dUutions of 1:50; 1:50 and 1:100, respectively. The source of the antibodies were for SSEAl (MC-480) and SSEA4 (MC-813-70) the Developmental Studies Hybridoma Bank, Iowa (USA) and anti-Oct4 (SC9081; H-134) was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, USA). After washing with PBS, antibody locaHzation was performed by using rabbit anti-mouse (SSEAl/4) and goat anti-rabbit (OCT4) immunoglobuHns conjugated to fluorescein isothiocyanate (Oregon Green®). Samples were analyzed on a Zeiss fluorescence microscope equiped with epifluorescence and a camera to record data. 4. Gene expression studies (a) RNA isolation and cDNA synthesis At the time of harvest, medium was aspirated and ceUs were lyzed using Ultraspec™(Biotecx) or Trizol® (Gibco BRL). RNA was isolated according to the instructions of the suppHers. RNA concentration was determined by measuring OD260 and equal amounts of RNA of the indicated ceU Hnes were subjected to conversion into cDNA. RNA was reversed transcribed using random primers and 15 units M-MuLV (Promega) in a reaction mixture containing 4μl 25mM MgC , 2μl of each of the four dNTPs at lOmM and 0.5μl RNasin (Promega) in a total volume of 20μl. RNA and 0.5 μg random hexamers were pre-incubated for 10 minutes at 55-60°. Mixtures were incubated at 37°C for 1 hour. (b) PCR reactions PCR was were performed using 2μl cDNA, 2.5 μl lOxSuperTaq buffer (without magnesium), 0.25 μl forward primer, 0.25 μl reverse primer, 0.50 μl lOmM dNTPs, 1.25 Units of SuperTaq polymerase. In the case of B2-microglobuHn 1.5mM MgCl2 was added to the reaction mixture. For mouse UTFl PCR, normal Taq polymerase (Roche) was used with a buffer containing MgCl 2 . The conditions for the PCR reaction were: 5 minutes 94°C; 28 cycles of 30 seconds 94°C, 30 seconds 60°C and 30 seconds 72°C; 10 minutes 72°C, using a PTC-200, Peltier Thermal cycler. PCR-fragments were run on a 2% agarose gel and visuaHzed by ethidium bromide staining. (c) PCR primers (1) human OCT4 : forward: CTCCTGGAGGGCCAGGAATC; reverse: CCACATCGGCCTGTGTATAT (2) mouse/human Oct4: forward: GAGTTGGTTCCACCTTCTCC; reverse GACACCTGGCTTCAGACTTC (3) mouse UTFl: forward: GTAAGAGGAGGAGAGCTG00; reverse CAGACTCTGCCTACTTACC (4) B2-microglobuHn: forward: CCAGCAGAGAATGGAAAGTC; reverse: GATGCTGCTTACATGTCTCG (5) mouse GAPDH: forward: ATCACCATCTTCCAGGAG; reverse: GGCATCCACAGTCCT (6) gp80: forward: CCAACCACGAAGGCTGTGCT; reverse GCTCCACTGGCCAAGGTCAA (7) LIF-R forward: CAACCAACAACATGCGAGTG; reverse GGTATTGCCGATCTGTCCTG (8) SOCS1: forward: CACGCACTTCCGCACATTCC; reverse TCCAGCAGCTCGAAGAGGCA (9) gpl30 forward: CCACATACGAAGACAGACCA; reverse GCGTTCTCTGACAACACACA 5. Isolation and injection of mouse blastocysts. Pre-implantation blastocysts were removed from the uteri of pregnant C57BL/6 mice on the third day of pregnancy according to estabhshed procedures. Human mesenchymal ceUs cultured according the instructions suppHer (Poietics) were trypsinized in trypsin/EDTA (Poietics) and taken up in 1 ml BMSCM medium containing 10 % charcoal treated foetal calf serum (FCS). Human bone marrow stem ceUs were quickly thawed from Hquid nitrogen and resuspended in 10 ml of DMEM medium containing 10% charcoal-treated FCS and centrifuged for 2 minutes at 850g. The peUeted ceUs were resuspended in 1 ml of DMEM supplemented with 10% charcoal-treated FCS. Approximately 20 ceUs were taken up by suction into a siHconied glass capUlary with a diameter that aUowed the ceUs to pass without damage. Approximately 10-12 ceUs were injected into the blastocoele of the blastocysts with the use of a Narashige micro-injector. The injected blastocysts were transferred into 200μl DMEM/10% FCS onto a non- tissue culture grade dish. To prevent Hquid evaporation, the incubation medium was covered by freshly distiUed paraffin oU. Embryos were cultured overnight at 37°C under a 5%CO2 atmosphere in a humidified incubator. On the morning of the foUowing day, the stiU non-adherent blastocysts were lysed in 100 microHter Ultraspec solution (BioTecx) for the isolationm of RNA. For immunofluorescence, the blastocysts were transferred with a glass capUlary into 200 μl DMEM supplemented with 10% FCS on a compartimentaHsed tissue culture plastic dish, and cultured for another 24 hours in DMEM/10% FCS. The now adherent blastocysts were fixed for 10 minutes at room temperature with a freshly prepared 4% formaldehyde solution in PBS. After three washes, the fixed samples were covered by a solution containing 50 mMTris pH7.4; 150 mM NaCl; 5 mM EDTA; 0.05% NP-40; 0.25% gelatin. For immunofluorescence, the ceUs were incubated with the first antibodies, washed and incubated with the secondary antibody. Immunofluorescence was recorded using an inverted Zeiss microscope equipped with epifluorescence Ulumination and a camera to record and store the data. Western blotting Proteins were separated by SDS-PAA gelelectrophoresis and transferred to a nitroceUulose membrane (Bio-rad) by electroblotting. The membrane was blocked for 30 min. in PBS containing 10% milk (Campina). After incubation with the primary antibody anti UTFl 1:200; anti-myc 1:500) for 1-2 hours, the membrane was washed 3 times with TBST. Species specific antibodies (1:3000) were incubated for 1 hour foUowed by washing with TBSB. The membrane was then incubated with a chemUuminescentie (ECL) solution (Roche) and revealed by the manufacturer's solution. Transient and stable transfection CeUs were transfected with 10 microgram of plasmid DNA in six weU plates using the Ca-phosphate co-precipitation method. After incubation with precipitate for 24 hours, the ceUs were washed with PBS and the medium was changed for new medium. CeUs were lysed with 200 microHter of lysis bi=uffer (PromegaO. Luciferase assays were performed according instructions of the suppHer (Promega). Each tranfection was carried out in tripHcate. To isolate stable transfectants, the pSV2Neo vector containing the neomycin resistance gene was transfected into P19 ceUs by calciumphosphate precipitation together with a plasmid containing the gene of of interst. Stable tranformants were selected with 400 micrograms of neomycin (G418) per ml. Colonies were picked with colony-rings. Examples Dedifferentiation experiments mouse Hematopoietic stem ceUs isolated from embryonic Hver of B6.SJL-Ly5.1 and eGFP transgenic mice are purified by Fluorescent Activated CeU Sorting (FACS). Hematopoietic stem ceUs are coUected on the basis of Lyδ.l expression. Pools of approximately 100 ceUs are injected in blastocysts of congenic C57BL/6 strain of mice expressing the Ly5.2 aUele. Injected blastocysts are disaggregated and Lyδ.l expressing ceUs are isolated by FACS and coUected as single ceUs. Sorted ceUs are coUected and maintained in media containing LIF and/or the MEK inhibitor. Oct4 expression is determined by single ceU RT-PCR using murine Oct-4-specific oHgonucleotide primers. Alternatively, mouse Hver hematopoietic stem ceUs are mixed with microsurgicaUy dissected inner ceU mass ceUs of blastocysts foUowed by the procedures described above. human Hematopoietic stem ceUs (CD34 positive) are injected into C57BL/6 or immunodeficient NOD-SCID or Rag-/- mouse blastocysts and expression of human Oct4 is determined by RT-PCR. Blastocysts injected with CD34-positive human hematopoietic ceUs transduced with Oct-4 promoter-eGFP fusion genes are assayed for eGFP and isolated by FACS. FACS sorted ceUs are maintained in LIF and MEK inhibitor containing media. 1. De-differentiation of human somatic stem ceUs foUowing micro-injection in mouse blastocysts To investigate whether the inner ceU mass of mouse pre-implantation embryos constitutes an environment which induces de-differentiation of somatic stem ceUs to ES-equivalent ceUs, two human stem ceU types i.e. human Mesenchymal Stem CeUs (hMSC) and human Hematopoietic Stem CeUs (AC133+ from cord blood, Poietics (BioWhittaker) were injected into mouse 3.5 day blastocysts. Between 10-12 ceUs were injected into the blastocoel. After culturing the injected blastocysts for 24 hours, RNA was isolated from the injected as weU as control embryos and analyzed for the expression of human OCT4. The remainder of the injected blastocysts was cultured for an additional 24 hours and prepared for immunofluorescence . Analysis of OCT4 expression (a) design of a human-specific OCT4 primer set To discriminate between human and mouse Oct4 transcripts in mixed mouse/human RNA samples containing both Oct4 orthologs, a human-specific OCT4 primer set was designed. The two primers of the human-specific primer set are located on separate exons and results in ampHfication of a human of 380 bp with RNA from human ceUs but not with RNA mouse ceUs. The UTF-1 transcript detected in RNA of mouse P19 EC ceUs indicates that the mouse RNA is intact. In RNA samples from human ceUs, the -RT reactions generates a much larger fragment indicative for amplification from genomic DNA. This band is not present in the human ceU derived RNA samples. Beta-2 microglobuhn expression is used as internal control. (b) Oct4 expression in hMSCs and hHSC's injected in mouse blastocysts Using the human-specific OCT4 primer set, OCT4 expression was analyzed in RNA samples isolated from the injected blastocysts. As summarized in Table 1, the injected hMSC express of OCT4. When normaHzed against the expression of beta2 microglobuhn in hMSC control the level of expressin of OCT4 is increased in hMSC and hHCS injected into blastocysts. By using the m/h OCT4 primer set, Oct4 expression is present in mouse, human and mixed RNA samples confirming the integrity of the RNA samples. (b) SSEA4 expression by blastocyst-injected hMSC and hHSC Unlike the ceUs of the inner ceU mass of the mouse blastocysts, both hMSC and hHSC show immunoreactivity against SSEA4 (Tabel 2). These results indicate that the blastocyst injected adult stem ceUs exhibit properties of ES-like ceUs as a results of incubation within the enviroment of the pre-implantation embryo. Example 2 De-differentiation of human Mesenchymal Stem CeUs by co-culture with P19 EC ceUs The inner ceU mass of pre-implantation mouse blastocysts represents an environment that leads to de-differentiation of adult or somatic stem ceUs representative of an ES ceU-Hke state. CeUs derived or resembhng the inner ceU mass of mouse blastocysts like undifferentiated EC ceUs may exhibit a simUar property. This property of EC ceUs can be demonstrated by co-culture of undifferentiated mouse P19 EC and hMSCs. P19 EC and hMSC were plated at different initiatial ceU densities to accommodate for the different growth rate of both ceU types. After 5 days of co-culture, the ceUs were analyzed for the expression human ES ceU-specific markers by immunofluorescence and RT-PCR. (a) analysis of SSEA4 expression Human mysenchymal stem ceUs in co-culture with P19 EC ceUs express the human-specific EC/ES ceU marker SSEA4, whUe this marker is hardly detectable in hMSCs in monoculture. To discriminate between P19 and hMSC in co-culture, the hMSC were labeled with the Hfe stain Dil. The co-locaHzation of Dil and SSEA4 confirms that SSEA4 expression is resulting from the hMSCs in the co-cultured ceUs (Figure 2). As control, the co-culteres were stained with SSEAl, which stains mouse P19 ceUs but not the hMSC. Results of this study are summarized in Table 3. (b) OCT4 expression in co-culteres of P19 and hMSC Expression of human OCT4 expression was analyzed in RNA of co-cultured P19 and hMSCs. As shown in Figure 3, human OCT4 is expressed at low levels in hMSC but could not be detected in the co-cultered hMSC even after 28 and 32 PCR cycles. In contract, the mouse/human primer set shows expression of Oct4 in both human MSCs and mouse P19 ceUs as weU as in the co-cultured ceUs. These combined results from the immunofluorescent and gene expression studies indicate that in co-culture with P19 ceUs, a smaU percentage of hMSCs has de- differentiated to an ES-like ceU expressing the stem ceU marker SSEA4. A larger fraction of hMSCs have differentiated into a ceU type in which OCT4 is no longer expressed biasing the detection of human OCT4 transcripts in mixed mouse/human RNA samples derived from the co-cultured ceUs. Example 3 Inhibition of HDAC expression by TSA Histon de-acetyelase (HDAC) activity has been shown to repress gene transcription through de-acetylation of histons, keeping chromatin in a condensated state. HDAC activity is inhibited by Trichostatin A (TSA). Human mesenchymal stem ceUs and mouse and human neuronal progenitor ceUs were treated by TSA at concentration of 10 and 50 ng/ml. After 24 and 48 hours, OCT4 expression was analyzed by RT-PCR. TSA treament for 24 to 48 hours enhances the expression of OCT4 in both human MSC and human Neural Progenitor CeUs as weU as in mouse neural progenitor ceUs. (Table 3). In Hne with the OCT4-UTF1-SMAD relationship, expression of UTFl was also increased leading to a reduction in TGF-beta, activin and BMP responsiveness of the TSA treated ceUs. Furthermore SSEA4 expression was increased in paraUel with upregulation of OCT4, indicating that upregulation of OCT4 resulted in de-differentiation of both human stem ceU types. TSA treated ceUs were aUowed to form embroid bodies by plating the ceUs on non-tissue culture grade plastics or in hanging droplets in the presence of retinoic acid or 1% DMSO. Visual inspection of the re-plated cultures revealed ceUs of different morphology compared to the parental cultures indicative for the appearance of ectoderm and mesoderm differentiated derivatives. Example 4 De-differentiation of hMSC by long term culture in defined media Human MSC were grown on a fibronectin coated dishes in DMEM containing PDGF-BB (0,1 -100 microgram/mi), EGF (0,1 to 100 microgram/ml), dexamethason (10-7-10-8 mM), ascorbic acid (0,1 to 10 mM), Hnoleic acid (0,1 to 10 microgram/ml) supUemented with 2% charcoal treated Fetal Calf serum (FCS) and cultured at densities between 10 3 to 5X10 3 ceUs per cm 2 . At initial plating, hMSCs express low levels of the human ES ceU markers Oct4 and SSEA4. CeUs cultured in this medium for more then 25 population doubhngs exhibit graduaUy increased Oct4 expression as determined by semi-quantitative PCR as weU as increased SSEA4 immunoreactivity (Table 4). Under these culturing conditions hMCS adopts a more de-differentiated phenotype resembHng that of human ES ceUs. The de-differentiated (ES-equivalent or ES- like ceUs) can be differentiated in vitro into a variety of ceU types including skeletal, smooth and cardiac muscle by treatment with 5-aza-cytidine, retinoic acid and BMP plus bFGF, respectively. In addition, endotheHal ceUs, hematopoietic precursers and mature blood ceUs, osteoblasts, chondroblasts and neuronal ceU types incuding neurons, astrocytes and gHa can be derived from these ceUs using procedures that are commonly used in obtaining these differentiated derivatives from ES ceUs. Example 5 LIF responsiveness and expression among stem ceU Hnes Gp 80 is differential expressed. Expression of genes that are part of the LIF signal transduction pathway, including LIF receptor, gpl30, SOCS1, STAT3 and IL-6 receptor gp80 was investigated in human ES ceUs, the human EC ceU Hne NteraD2 and hMSC Iable . In aU three ceU Hnes, LIF receptor, gpl30 and STAT3 are expressed at comparable levels (Table 5). In human NteraD2 ceUs LIF-induced STAT3 tyrosine 705 is blocked. The high level expression of SOCSl, which inhibits the JAK-2 tyrosine protein kinase may be responsible for the observed LIF resistence of human EC and ES ceUs. hMSCs express the IL-6 receptor gp80. Since hES ceUs do not express gp80, loss of expression of this gene is a marker for de-differentiation of these into an ES-like ceU. Example 6 The transcription factor UTFl binds to the sequence CAGACAG referred to as SMAD binding element (SBE) as identified in the JunB promoter ( Jonk et al.,). UTFl (indicated as clone 8.8 in Figure 4) was in vitro translated as a Myc-UTFl fusion protein and aUowed to form a DNA-protein complex with a double stranded biotinylated CAGAGACGTCTCTG probe and protein binding was detected by Western blotting. Overexpression of UTFl blocks Smad-dependent transactivation of the JunB (SBE)4-LUC reporter in transient transfection assays. Transient overexpression of UTFl blocks Smadl plus Smad4, Smad2 plus Smad4 and Smad3 plus Smad4 transactivation both in the absence as weU as in the presence of a stimulary Hgand (TGF-beta, Activin, BMP) (Figure 5). UTFl ehcited repression of SMAD- dependent transactivation is observed in transiently transfected ceUs that endogenously express UTFl (P19 EC, NteraD2) as weU as in ceUs in which UTFl is not expressed. Stable expression of UTFl in P19 EC ceUs or a clonaUy isolated variant of this ceU Hne blocks RA- and DMSO-induced differentiation as indicated by maintenance of expression of SSEAl immunoreactivity of the UTFl expressing P19 ceUs up to several days after the induction of differentiation. Constitutive expression of UTFl faUs to induce the expression of Smad-regulated target genes by TGF-beta, BMP and Activin and related fa Uy members. Table 1. Analysis of human Oct4 expression in human Mesenchymal Stem CeUs (hMSC) and human Hematopoietic Stem CeUs (hHSC) injected in 3.5 day mouse blastocysts. (A) human OCT4 and beta 2 microglobuhn expression in non-injected embryo (control, no inj.), P19 EC ceUs, injected hMSC, injected hHSC, not injected hMSC, and non injected NteraD2. Lane -RT is PCR on non-reverse transcriptase treated RNA. (B) mouse and human Oct4 and mouse GAPDH expression in same samples as under (A). (-) no expression; (+/-) expression detectable; (+) clear expression; (++) strong expression. A B Table 2. SSEA4 staining of hMSC and hHSC injected into 3.5 day mouse blastocysts and non-injected ceUs. Control blastocyst were non-injected. DAPI was used to stain nuclei. Table 3. Analysis of SSEA4 expression in human Mesenchymal Stem CeUs (hMSC) co- cultured with mouse P19 EC ceUs. Controls: SSEAl expression in mouse P19 EC ceUs and SSEA4 expression in hMSC. (-) no expression; (+/-) expression detectable; (+) clear expression; (++) strong expression Table 4. OCT4 expression after TSA treatment. hMSC: human Mesenchymal Stem CeUs; hNPC: human Neural Progenitor CeUs; mNPC: mouse Neural Progenitor CeUs isolated from day 14 mouse brain of eGFP and bcl2 transgenic mice. TSA was used at 10 and 50 ng/ml. Oct4 expression was determined by RT-PCR and quantiated as foUows: +/- expression detectable; (+) clear expression; (++) strong expression. ND: not determined. Table 5. Long-term culture of hMSC in de-differentiation inducing media. OCT4 expression was determined by RT-PCR. UTFl expression was determined by Western blotting. SSEA4 expression was determined by immunofluorescence. BMP/TGF-beta/activin response was determined by transient transfection of the (SBE)4-luc reporter. LF responsiveness was determined by analysis of STAT3 tyr 705 and STAT3 ser 727 phosphorylation using STAT3 phosphospecific antibodies. (-) no expression or no response; (+/-) low expression or response; (+) clear expression or response ; (++) strong expression or response. Table 6. Expression of genes involved in LIF signal transduction in human and mouse ES and EC ceUs by RT-PCR. Human ES (human embryonic stem ceUs; NteraD2: human Embryonal Carcinoma ceUs; hMSC: human Mesenchymal Stem CeUs; P19 EC: mouse embryonal carcinoma ceUs. m/h indicates that the primers hybridize with sequences of both human and mouse orthologs. (-) no expression; (+/-) expression detectable; (+) clear expression; (++) strong expression gp80: glycoprotein 80 or IL-6 receptor; SOCSl: suppressor of cytokine signahng 1; STAT3: signal tranducer and activator of transcription3; b2 micr: beta2- microglobuhn.

Claims: Claims 1. A method for obtaining a stem ceU-Hke ceU from a sample taken from a multiceUular organism comprising culturing ceUs from said sample and aUowing for transcription, translation or expression by at least one of said ceUs of a gene or fragment thereof that in general is differentiaUy expressed at different phases of embryonic development. 2. A method according to claim 1 wherein said organism is functionaUy differentiated . 3. A method according to claim 1 or 2 wherein said organism comprises a vertebrate. 4. A method according to anyone of claims 1 to 3 comprising culturing ceUs from said sample in the relative absence of a differentiation factor 5. A method according to claim 4 wherein said factor comprises retinoid activity. 6. A method according to anyone of claims 1 to 5 wherein said gene is overexpressed in an early phase of embryonic development. 7. A method according to claim 6 wherein said early phase comprises the blastula stage. 8. A method according to claim 7 wherein, in mammals, said blastula stage comprises a pre-implantation stage. 9. A method according to anyone of claims 1 to 8 wherein said gene comprises Oct 4 or orthologue thereof. 10. A method according to anyone of claims 1-9 further comprising selecting said stem ceU-Hke ceU by detection of expression of ceU surface markers stage specific embryonic antigen. 11. A method according to claim 10 wherein said antigen comprises SSEA-1, SSEA-3, SSEA-4, TRA-1-60 , TRA-1-81 and/or alkaHne phosphatase or analogue thereof. 12. A dedifferentiated stem ceU. 13. A stem ceU Hke ceU obtainable by a method according to anyone of claims 1- 11. 14. A ceU according to claim 12 or 13 comprising a recombinant nucleic acid. 15. A culture comprising a ceU according to claim 12 to 14. 16. A graft or transplantation material comprising a ceU according to anyone of claims 12 to 14 or a culture according to claim 15. 17. An animal comprising a ceU according to anyone of claims 12 to 14 or a culture according to claim 15. 18. Use of a ceU according to anyone of claims 12 to 14 or a culture according to claim 15. 19. Use according to claim 18 for the preparation of a pharmaceutical composition. 20. Use according to claim 19 for the preparation of a pharmaceutical composition for the treatment of an individual with a graft. 21. Use according to claim 20 wherein said individual or a sample thereof comprises a source of said graft. 22. Use according to claim 18 for cloning of an animal. 23. Use according to claim 22 wherein said animal comprises an experimental animal, or a farm animal or an animal for xenotransplant production.

Inventors: KRUIJER WIEBE, KRUIJER, WIEBE
Applicants: FORNIX BIOSCIENCES N V, KRUIJER WIEBE, UNIV GRONINGEN, FORNIX BIOSCIENCES N.V., KRUIJER, WIEBE, RIJKSUNIVERSITEIT GRONINGEN
Application year: 2001
Main classification: C12N5
IPC codes: A61K35, C12N5